Ptc Therapeutics logo

Ptc Therapeutics share price today

(NASDAQ: PTCT)

Ptc Therapeutics share price is $46.18 & ₹3,994.11 as on 24 Jan 2025, 2.30 'hrs' IST

$46.18

1.1

(2.44%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Ptc Therapeutics share price in Dollar and Rupees. Guide to invest in Ptc Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ptc Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Ptc Therapeutics share price movements

  • Today's Low: $44.30
    Today's High: $46.51

    Day's Volatility :4.75%

  • 52 Weeks Low: $23.58
    52 Weeks High: $54.16

    52 Weeks Volatility :56.46%

Ptc Therapeutics Returns

PeriodPtc Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
10.63%
-5.5%
0.0%
6 Months
32.24%
-4.3%
0.0%
1 Year
69.09%
1.6%
0.0%
3 Years
15.15%
9.8%
-11.0%

Ptc Therapeutics Key Statistics

in dollars & INR

Previous Close
$45.08
Open
$44.86
Today's High
$46.51
Today's Low
$44.3
Market Capitalization
$3.5B
Today's Volume
$569.2K
52 Week High
$54.16
52 Week Low
$23.58
Revenue TTM
$900.7M
EBITDA
$21.8M
Earnings Per Share (EPS)
$-5.94
Profit Margin
-50.32%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-7740.12%

How to invest in Ptc Therapeutics Stock (PTCT) from India?

It is very easy for Indian residents to invest directly in Ptc Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ptc Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ptc Therapeutics or PTCT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ptc Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ptc Therapeutics shares which would translate to 0.019 fractional shares of Ptc Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ptc Therapeutics, in just a few clicks!

Returns in Ptc Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ptc Therapeutics investment value today

Current value as on today

₹1,77,273

Returns

₹77,273

(+77.27%)

Returns from Ptc Therapeutics Stock

₹73,218 (+73.22%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Ptc Therapeutics

-61%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Ptc Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -61% less investors are searching Ptc Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Ptc Therapeutics

  • Vanguard Group Inc

    11.83%

  • BlackRock Inc

    10.35%

  • Wellington Management Company LLP

    10.23%

  • RTW INVESTMENTS, LLC

    9.59%

  • Armistice Capital, LLC

    9.38%

  • COWEN AND COMPANY, LLC

    4.66%

Analyst Recommendation on Ptc Therapeutics

Buy

    50%Buy

    30%Hold

    20%Sell

Based on 20 Wall street analysts offering stock ratings for Ptc Therapeutics(by analysts ranked 0 to 5 stars)

Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
5
5
Hold
6
6
7
Sell
4
8
8

Analyst Forecast on Ptc Therapeutics

What analysts predicted

Upside of 24.98%

Target:

$57.71

Current:

$46.18

Insights on Ptc Therapeutics

  • Price Movement

    In the last 7 days, PTCT stock has moved up by 4.6%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 186.70M → 196.78M (in $), with an average increase of 5.1% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -91.57M → -106.65M (in $), with an average decrease of 7.9% per quarter
  • PTCT vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 79.3%

Ptc Therapeutics Financials in INR & Dollars

FY18Y/Y Change
Revenue
$264.7M
↑ 36.19%
Net Income
$-128.1M
↑ 62.13%
Net Profit Margin
-48.38%
↓ 7.74%
FY19Y/Y Change
Revenue
$307.0M
↑ 15.96%
Net Income
$-251.6M
↑ 96.42%
Net Profit Margin
-81.95%
↓ 33.57%
FY20Y/Y Change
Revenue
$380.8M
↑ 24.04%
Net Income
$-438.2M
↑ 74.17%
Net Profit Margin
-115.07%
↓ 33.12%
FY21Y/Y Change
Revenue
$538.6M
↑ 41.45%
Net Income
$-523.9M
↑ 19.57%
Net Profit Margin
-97.27%
↑ 17.8%
FY22Y/Y Change
Revenue
$698.8M
↑ 29.75%
Net Income
$-559.0M
↑ 6.7%
Net Profit Margin
-80.0%
↑ 17.27%
FY23Y/Y Change
Revenue
$937.8M
↑ 34.2%
Net Income
$-626.6M
↑ 12.09%
Net Profit Margin
-66.81%
↑ 13.19%
Q2 FY23Q/Q Change
Revenue
$213.8M
↓ 2.98%
Net Income
$-198.9M
↑ 43.12%
Net Profit Margin
-93.02%
↓ 29.97%
Q3 FY23Q/Q Change
Revenue
$196.6M
↓ 8.06%
Net Income
$-133.0M
↓ 33.14%
Net Profit Margin
-67.64%
↑ 25.38%
Q4 FY23Q/Q Change
Revenue
$307.1M
↑ 56.2%
Net Income
$-155.8M
↑ 17.16%
Net Profit Margin
-50.74%
↑ 16.9%
Q1 FY24Q/Q Change
Revenue
$210.1M
↓ 31.57%
Net Income
$-91.6M
↓ 41.22%
Net Profit Margin
-43.58%
↑ 7.16%
Q2 FY24Q/Q Change
Revenue
$186.7M
↓ 11.14%
Net Income
$-99.2M
↑ 8.3%
Net Profit Margin
-53.12%
↓ 9.54%
Q3 FY24Q/Q Change
Revenue
$196.8M
↑ 5.4%
Net Income
$-106.7M
↑ 7.54%
Net Profit Margin
-54.2%
↓ 1.08%
FY18Y/Y Change
Profit
$252.1M
↑ 32.79%
FY19Y/Y Change
Profit
$294.8M
↑ 16.97%
FY20Y/Y Change
Profit
$361.8M
↑ 22.72%
FY21Y/Y Change
Profit
$506.3M
↑ 39.92%
FY22Y/Y Change
Profit
$654.1M
↑ 29.21%
FY23Y/Y Change
Profit
$872.3M
↑ 33.36%
Q2 FY23Q/Q Change
Profit
$201.1M
↓ 2.5%
Q3 FY23Q/Q Change
Profit
$187.1M
↓ 6.96%
Q4 FY23Q/Q Change
Profit
$200.8M
↑ 7.31%
Q1 FY24Q/Q Change
Profit
$143.8M
↓ 28.35%
Q2 FY24Q/Q Change
Profit
$168.3M
↑ 17.01%
Q3 FY24Q/Q Change
Profit
$185.9M
↑ 10.47%
FY18Y/Y Change
Operating Cash Flow
$-27.6M
↑ 174.68%
Investing Cash Flow
$-42.6M
↓ 424.87%
Financing Cash Flow
$131.6M
↑ 197.55%
FY19Y/Y Change
Operating Cash Flow
$-98.6M
↑ 256.86%
Investing Cash Flow
$-387.2M
↑ 808.73%
Financing Cash Flow
$613.2M
↑ 366.07%
FY20Y/Y Change
Operating Cash Flow
$-194.1M
↑ 96.75%
Investing Cash Flow
$-561.5M
↑ 45.01%
Financing Cash Flow
$668.7M
↑ 9.05%
FY21Y/Y Change
Operating Cash Flow
$-251.3M
↑ 29.51%
Investing Cash Flow
$219.2M
↓ 139.03%
Financing Cash Flow
$20.9M
↓ 96.88%
FY22Y/Y Change
Operating Cash Flow
$-356.7M
↑ 41.91%
Investing Cash Flow
$290.2M
↑ 32.39%
Financing Cash Flow
$168.0M
↑ 704.48%
Q2 FY23Q/Q Change
Operating Cash Flow
$-14.1M
↓ 52.12%
Investing Cash Flow
$-23.8M
↓ 18.01%
Financing Cash Flow
$18.5M
↑ 350.9%

Ptc Therapeutics Technicals Summary

Sell

Neutral

Buy

Ptc Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Ptc Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ptc Therapeutics, Inc. logo
-1.66%
32.24%
69.09%
15.15%
-11.76%
Biontech Se logo
0.91%
34.01%
18.85%
-26.4%
246.9%
Regeneron Pharmaceuticals, Inc. logo
-4.82%
-36.95%
-28.33%
12.74%
100.35%
Vertex Pharmaceuticals Incorporated logo
4.86%
-13.58%
-0.46%
88.45%
88.24%
Alnylam Pharmaceuticals, Inc. logo
9.57%
13.5%
44.91%
103.56%
127.75%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ptc Therapeutics, Inc. logo
NA
NA
0.81
-4.25
-77.4
-0.05
NA
-13.7
Biontech Se logo
160.8
NA
0.04
-3.33
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
17.02
17.02
1.05
44.99
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.1
0.48
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ptc Therapeutics, Inc. logo
Buy
$3.5B
-11.76%
NA
-50.32%
Biontech Se logo
Buy
$28.1B
246.9%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$75.6B
100.35%
17.02
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$110.2B
88.24%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$34.2B
127.75%
NA
-15.86%

Ptc Therapeutics Dividend announcements

  • Ptc Therapeutics Earnings

    Ptc Therapeutics’s price-to-earnings ratio stands at None

    Read More

About Ptc Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Organization
Ptc Therapeutics
Employees
988
CEO
Dr. Stuart W. Peltz Ph.D.
Industry
Health Technology

Management People of Ptc Therapeutics

NameTitle
Dr. Stuart W. Peltz Ph.D.
Co-Founder, Senior Consultant & Member of Scientific Advisory Board
Dr. Allan Steven Jacobson Ph.D.
Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Mr. Pierre Gravier M.S.
Chief Financial Officer
Mr. Mark Elliott Boulding J.D.
Executive VP & Chief Legal Officer
Mr. Eric Pauwels
Chief Business Officer
Dr. Lee Golden M.D., Ph.D.
Executive VP & Chief Medical Officer
Ms. Christine Utter CPA
Senior VP, Chief Accounting Officer & Head of People Services
Dr. Neil Almstead Ph.D.
Chief Technical Operations Officer
Ms. Linda Montella Carter
Senior VP & Chief Information Officer

Important FAQs about investing in Ptc Therapeutics (PTCT) from India :

What is Ptc Therapeutics share price today?

Ptc Therapeutics share price today stands at $46.18, Open: $44.86 ; Previous Close: $45.08 ; High: $46.51 ; Low: $44.30 ; 52 Week High: $54.16 ; 52 Week Low: $23.58. The stock opens at $44.86, after a previous close of $45.08. The stock reached a daily high of $46.51 and a low of $44.30, with a 52-week high of $54.16 and a 52-week low of $23.58.

Can Indians buy Ptc Therapeutics shares?

Yes, Indians can invest in the Ptc Therapeutics (PTCT) from India.

With INDmoney, you can buy Ptc Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Ptc Therapeutics at zero transaction cost.

How can I buy Ptc Therapeutics shares from India?

It is very easy to buy Ptc Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ptc Therapeutics be purchased?

Yes, you can buy fractional shares of Ptc Therapeutics with INDmoney app.

What are the documents required to start investing in Ptc Therapeutics stocks?

To start investing in Ptc Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Ptc Therapeutics

Today’s highest price of Ptc Therapeutics (PTCT) is $46.51.

Today’s lowest price of Ptc Therapeutics (PTCT) is $44.30.

What is today's market capitalisation of Ptc Therapeutics

Today's market capitalisation of Ptc Therapeutics PTCT is 3.5B

What is the 52 Week High and Low Range of Ptc Therapeutics

  • 52 Week High

    $54.16

  • 52 Week Low

    $23.58

What are the historical returns of Ptc Therapeutics?

  • 1 Month Returns

    -1.66%

  • 3 Months Returns

    32.24%

  • 1 Year Returns

    69.09%

  • 5 Years Returns

    -11.76%

Who is the Chief Executive Officer (CEO) of Ptc Therapeutics

Dr. Stuart W. Peltz Ph.D. is the current Chief Executive Officer (CEO) of Ptc Therapeutics.